Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis
Jae‐Won Hyun(Seoul National University Hospital), Ho Jin Kim(National Cancer Center), So‐Young Huh(Kosin University Gospel Hospital), In Soo Joo(Ajou University), Joong‐Yang Cho(Inje University Ilsan Paik Hospital), Jeeyoung Oh(Université Paris-Sud), Kee Duk Park(Ewha Womans University), Su‐Hyun Kim(National Cancer Center), Nam‐Hee Kim(Korea National Institute of Health), Suk-Won Ahn(Chung-Ang University Hospital), In Hye Jeong(National Cancer Center), Min Su Park(Yeungnam University College), Ju‐Hong Min(Samsung Medical Center), Byoung Joon Kim(Samsung Medical Center), Young In Eom(Ajou University), Eun Bin Cho(Changwon National University)
Cited by 19
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284